Letter by Campochiaro et al Regarding Article, “Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
In their article on immune checkpoint inhibitor (ICI)–related cardiotoxicity, Escudier et al1 elegantly summarized the clinical features, management, and outcomes of cancer patients from 2 different cardio-oncology centers who developed immune-related cardiac-side effects after treatment with ICIs. There is presently no clear consensus for diagnosing ICI-related cardiotoxicity, which results in remarkable diagnostic heterogeneity. As recently reported,2 immune-mediated myocarditis is the most plausible pathological mechanism by which ICIs can cause cardiotoxicity. At present, the diagnostic gold standard for myocarditis is …